Cephalon’s Oncologic Treanda On Track For Q4 NDA Filing
This article was originally published in The Pink Sheet Daily
Executive Summary
Firm's initial goal is non-Hodgkin's lymphoma, but plans are in place for studies in chronic lymphocytic leukemia, mantle cell lymphoma and small-cell lung.
You may also be interested in...
Cephalon On Track To File Treanda For Second Cancer Indication By Year-End
Bendamustine meets both primary endpoints in Phase III for relapsed, rituximab-refractory non-Hodgkin’s lymphoma.
Cephalon On Track To File Treanda For Second Cancer Indication By Year-End
Bendamustine meets both primary endpoints in Phase III for relapsed, rituximab-refractory non-Hodgkin’s lymphoma.
Cephalon To File Treanda For Two Oncology Indications This Year
Company is on track to file chronic lymphocytic leukemia indication in Q3, followed by non-Hodgkin’s lymphoma in Q4.